We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MedXY AI/MedXY News/Tag: CAR T-cell therapy

MedXY News

EnglishTag

CAR T-cell therapy

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity cardiovascular risk atrial fibrillation biomarkers critical care clinical trials Hypertension artificial intelligence Cardiology oncology public health type 1 diabetes diabetes Mortality Alzheimer's disease cardiovascular disease breast cancer epidemiology

Latest news

Tag

$Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study$

Hematology-OncologyLarge B-Cell LymphomaCAR T-cell therapy

Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study

By MedXY|Sep 18, 2026

Lisocabtagene maraleucel demonstrates durable five-year survival and potential cure in relapsed/refractory large B-cell lymphoma, with manageable long-term safety, based on data from the TRANSCEND NHL 001 trial and its long-term follow-up.

$Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis$

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

Hematology-Oncology

relapsed/refractory

BCMA

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

By MedXY|Sep 13, 2026

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and saf

$Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple Myeloma$

Hematology-Oncologyrelapsed/refractoryGPRC5D

Arlocabtagene Autoleucel: Advancing Treatment Paradigms in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

By MedXY|Sep 12, 2026

Arlocabtagene autoleucel (arlo-cel) is a novel GPRC5D-targeted CAR T-cell therapy showing promising efficacy and manageable safety in patients with relapsed/refractory multiple myeloma heavily pretreated with standard regimens, including pr

$Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia$

Hematology-Oncologypediatric oncologyCAR T-cell therapy

Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

By MedXY|Sep 6, 2026

A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.

Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal Cancers

GastroenterologyCA19-9CAR T-cell therapy

Targeting the CA19-9 Glycan: A Promising CAR T Cell Therapy for Pancreatic and Gastrointestinal Cancers

By MedXY|Aug 29, 2026

CAR T cells targeting the CA19-9 glycan show potent, specific anti-tumor activity in pancreatic and various gastrointestinal cancers, providing new avenues for immunotherapy of hard-to-treat solid tumors.

Immunosenescence as a Key Barrier to CD19 CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

Hematology-OncologyImmunosenescenceCD19

Immunosenescence as a Key Barrier to CD19 CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

By MedXY|Aug 27, 2026

This article explores how T-cell immunosenescence impairs the efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia, highlighting potential therapeutic strategies to overcome this barrier.

TP53-Mutated Clonal Hematopoiesis Drives Pro-Inflammatory Phenotype and Predicts Poor Outcomes After CAR T-Cell Therapy

Hematology-OncologyinflammationCAR T-cell therapy

TP53-Mutated Clonal Hematopoiesis Drives Pro-Inflammatory Phenotype and Predicts Poor Outcomes After CAR T-Cell Therapy

By MedXY|Aug 26, 2026

TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.

$Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease$

Hematology-OncologyGPRC5DBCMA

Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease

By MedXY|Aug 20, 2026

Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.

$Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma$

Hematology-OncologyLarge B-Cell LymphomaCAR T-cell therapy

Prognostic Impact of IPI Risk Factors on CAR T-Cell Therapy Versus Allogeneic Stem Cell Transplantation in Relapsed/Refractory Large B-Cell Lymphoma

By MedXY|Aug 17, 2026

This study compares outcomes of CAR T-cell therapy and allogeneic stem cell transplantation based on IPI risk factors in relapsed/refractory LBCL, highlighting favorable survival with CAR T-cell therapy in low-risk patients but advocating a

$Ultralow-Dose IL-10–Expressing CAR T Cells Show Promising Activity in Relapsed/Refractory DLBCL$

Hematology-OncologyCAR T-cell therapyDiffuse large B-cell lymphoma

Ultralow-Dose IL-10–Expressing CAR T Cells Show Promising Activity in Relapsed/Refractory DLBCL

By MedXY|Jul 25, 2026

A phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells in 13 patients with R/R DLBCL reported a 92.3% objective response rate with manageable safety.

Linperlisib Potentiates MUC1-Tn CAR T Cell Therapy by Suppressing the EGR1/DUSP2 Axis to Combat T-Cell Acute Lymphoblastic Leukemia

Hematology-OncologyCAR T-cell therapyLinperlisib

Linperlisib Potentiates MUC1-Tn CAR T Cell Therapy by Suppressing the EGR1/DUSP2 Axis to Combat T-Cell Acute Lymphoblastic Leukemia

By MedXY|Jul 6, 2026

This study highlights how linperlisib, a PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell efficacy in T-ALL by preventing T cell exhaustion via suppression of the EGR1/DUSP2 pathway, improving anti-leukemic activity and persistence.

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Hematology-OncologyB-ALLCAR T-cell therapy

Cellular and Molecular Mechanisms of Relapse After CD19/CD22 Dual-Target CAR T-Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

By MedXY|Jun 2, 2026

A study of 91 B-ALL patients found that relapse after CD19/CD22 dual-target CAR T-cell therapy is mainly driven by CAR T-cell functional failure and antigen loss, with PAX5 mutations linked to early immune escape.

CAR T-Cell Therapy Targeting CD117 Shows Promise Against Advanced Systemic Mastocytosis in Preclinical Studies

Hematology-OncologyCAR T-cell therapyCD117 targeting

CAR T-Cell Therapy Targeting CD117 Shows Promise Against Advanced Systemic Mastocytosis in Preclinical Studies

By MedXY|May 11, 2026

Anti-CD117 CAR T-cell therapy demonstrated potent elimination of malignant mast cells in preclinical models of advanced systemic mastocytosis, offering a potential new treatment approach for this aggressive disorder.

Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma

Hematology-OncologyCAR T-cell therapyChronobiology

Study Finds Infusion Timing Does Not Affect CAR T-Cell Therapy Outcomes for Large B-Cell Lymphoma

By MedXY|May 11, 2026

A retrospective study of 584 Australian lymphoma patients shows no significant link between CAR T-cell infusion timing and treatment outcomes, suggesting chronobiology may not influence results in large B-cell lymphoma therapy.

Donor-Derived VCAR33 CAR T-Cell Therapy Shows Promise in High-Risk AML Post-Transplant

Hematology-OncologyAMLCAR T-cell therapy

Donor-Derived VCAR33 CAR T-Cell Therapy Shows Promise in High-Risk AML Post-Transplant

By MedXY|Apr 27, 2026

VCAR33, a donor-derived anti-CD33 CAR T-cell therapy, demonstrated acceptable safety and preliminary efficacy in relapsed/refractory AML/MDS after allogeneic HCT, with 20% overall response rate and manageable toxicities.

$TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL$

Hematology-OncologyB細胞急性リンパ性白血病CAR T-cell therapy

TP53 Alterations Emerge as Critical Adverse Prognostic Factor in Pediatric and Young Adult Patients Treated with CD19-CAR T-Cell Therapy for Relapsed/Refractory B-ALL

By MedXY|Apr 12, 2026

A single-center retrospective study of 69 pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia reveals that TP53 alterations significantly compromise outcomes following tisagenlecleucel therapy. Pa

Global Disparities in CAR T-Cell Access: HTA Analysis Reveals Only Half of G20 Countries Recommend Reimbursement

Hematology-OncologyCAR T-cell therapyGlobal access

Global Disparities in CAR T-Cell Access: HTA Analysis Reveals Only Half of G20 Countries Recommend Reimbursement

By MedXY|Apr 11, 2026

A cross-sectional analysis of health technology assessments across G20 nations reveals significant disparities in access to CAR T-cell therapies, with only 48% of approved indications recommended for reimbursement and a median 1.54-year del

Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL

Hematology-OncologyCAR T-cell therapyimmunotherapy

Fractionated Dosing of Varnimcabtagene Autoleucel Delivers Deep Remissions and Enhanced Safety in Adult B-ALL

By MedXY|Feb 18, 2026

The CART19-BE-02 phase 2 trial demonstrates that varnimcabtagene autoleucel, utilizing a unique fractionated dose escalation strategy, achieves an 84.4% MRD-negative complete response rate in adults with relapsed or refractory B-ALL while s

Engineering a Cure: How CAR T-Cell Therapy is Transforming the Fight Against Autoimmune Hemolytic Anemia

Allergy & ImmunologyAutoimmune diseasebệnh huyết học

Engineering a Cure: How CAR T-Cell Therapy is Transforming the Fight Against Autoimmune Hemolytic Anemia

By MedXY|Jan 14, 2026

A groundbreaking study shows that CD19 CAR T-cell therapy can induce sustained, drug-free remission in patients with severe, multirefractory autoimmune hemolytic anemia by successfully eliminating the autoreactive B-cells that drive the dis

$Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL$

newsCAR T-cell therapyDLBCL

Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL

By MedXY|Jan 13, 2026

The ZUMA-6 trial investigated combining axicabtagene ciloleucel with atezolizumab for refractory DLBCL. While the combination was safe with a 54% complete response rate, efficacy and CAR T-cell expansion were comparable to monotherapy, high

1 / 2

12

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

How often should a couple have sex?

Intimate Health

Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Intimate Health

What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities